Isogenica will be talking at Lonza’s ‘Conquering Complexity for Novel Biotherapeutics – From Concept to Clinic’ event hosted by One Nucleus.
Dr Edward McGowan, Isogenica’s Senior Director of Discovery and Development will be discussing ‘Bispecific Discovery: where do we start – and where are we going?’ from 9:50-10:15am. This presentation will take us through Isogenica’s innovative approach to VHH discovery, covering our synthetic platform’s unique advantages over alternative immune–based methods, highlighting the advantageous features of the VHH when utilised in multivalent targeting approaches over alternative IgG based entities and their versatility of use in a range of therapeutic areas.
Event date: 29th of March 2021
Contact BD@isogenica.com for further information or for an opportunity learn about the latest developments at Isogenica.